We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 418.32%
This Fund
S&P 500
This Quarter Est. Return
+40.72%
1 Year Est. Return
+418.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$158M
AUM Growth
+$18.4M
Cap. Flow
-$14.8M
Cap. Flow %
-9.34%
Top 10 Hldgs %
63.75%
Holding
43
New
8
Increased
13
Reduced
9
Closed
11

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$9.26M
2
RVMD icon
Revolution Medicines
RVMD
+$7.46M
3
GMAB icon
Genmab
GMAB
+$6.22M
4
COGT icon
Cogent Biosciences
COGT
+$4.13M
5
TRVI icon
Trevi Therapeutics
TRVI
+$3.97M

Top Sells

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$16.9M
2
URGN icon
UroGen Pharma
URGN
+$5.31M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.92M
4
IMVT icon
Immunovant
IMVT
+$4.55M
5
IQV icon
IQVIA
IQV
+$4.38M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.03B
$13.3M 8.39%
343,284
+118,126
+52% +$4.13M
AXSM icon
2
Axsome Therapeutics
AXSM
$10.8B
$13.2M 8.33%
53,916
+42,699
+381% +$9.26M
GMAB icon
3
Genmab
GMAB
$20.7B
$11.8M 7.47%
430,600
+233,891
+119% +$6.22M
CLDX icon
4
Celldex Therapeutics
CLDX
$3.12B
$10.7M 6.76%
287,583
+107,535
+60% +$3.47M
TRVI icon
5
Trevi Therapeutics
TRVI
$2.46B
$9.78M 6.17%
524,224
+272,658
+108% +$3.97M
RVMD icon
6
Revolution Medicines
RVMD
$45B
$9.56M 6.04%
+51,053
New +$7.46M
DFTX
7
Definium Therapeutics
DFTX
$5.12B
$8.86M 5.59%
188,282
-163,179
-46% -$4.03M
VIR icon
8
Vir Biotechnology
VIR
$1.93B
$8.7M 5.49%
853,685
+123,137
+17% +$1.17M
IMVT icon
9
Immunovant
IMVT
$8.11B
$8.03M 5.07%
208,368
-149,238
-42% -$4.55M
URGN icon
10
UroGen Pharma
URGN
$2.16B
$7.04M 4.45%
191,313
-196,058
-51% -$5.31M
CLYM
11
Climb Bio
CLYM
$891M
$6.79M 4.29%
521,082
+321,873
+162% +$3.32M
ANL
12
Adlai Nortye Group ADS
ANL
$967M
$6.35M 4.01%
552,501
+137,649
+33% +$1.67M
SVRA icon
13
Savara
SVRA
$1.1B
$6.02M 3.8%
977,460
-608,517
-38% -$3.27M
MPLT
14
MapLight Therapeutics
MPLT
$639M
$4.5M 2.84%
125,432
-66,707
-35% -$1.92M
ORIC icon
15
Oric Pharmaceuticals
ORIC
$1.33B
$4.4M 2.78%
406,077
+290,843
+252% +$2.64M
UTHR icon
16
United Therapeutics
UTHR
$20.9B
$3.89M 2.45%
7,172
+1,986
+38% +$1.12M
PCVX icon
17
Vaxcyte
PCVX
$9.1B
$3.88M 2.45%
66,793
-43,661
-40% -$2.37M
ONC
18
BeOne Medicines Ltd
ONC
$40.5B
$3.5M 2.21%
+12,273
New +$3.62M
CABA icon
19
Cabaletta Bio
CABA
$588M
$3.48M 2.2%
1,278,652
+212,413
+20% +$699K
ZLAB icon
20
Zai Lab
ZLAB
$2.94B
$2.96M 1.87%
155,813
-120,005
-44% -$2.37M
SION
21
Sionna Therapeutics
SION
$325M
$2.78M 1.75%
63,156
-77,868
-55% -$3.11M
DRUG
22
Bright Minds Biosciences
DRUG
$639M
$2.14M 1.35%
30,456
+17,145
+129% +$1.35M
ACRS icon
23
Aclaris Therapeutics
ACRS
$908M
$1.36M 0.86%
257,675
-108,815
-30% -$485K
HELP
24
Cybin Inc
HELP
$893M
$1.35M 0.85%
+204,424
New +$1.02M
KNSA icon
25
Kiniksa Pharmaceuticals
KNSA
$6.08B
$1.21M 0.76%
+18,867
New +$979K
1
2

Similar funds

FCM
Flagship Capital Management Media, Pennsylvania $158M AUM
SF
Seek First Campbell, California $158M AUM 38.46% 1-Year Est. Return
CCA
Collaborative Capital Advisors New York $158M AUM
VFIA
Virtus Fixed Income Advisers Hartford, Connecticut $158M AUM 0.51% 1-Year Est. Return
BTC
Bank & Trust Company Litchfield, Illinois $158M AUM 35.48% 1-Year Est. Return
SWM
Schwallier Wealth Management Grand Rapids, Michigan $158M AUM 16.81% 1-Year Est. Return
AWA
AGH Wealth Advisors Wichita, Kansas $158M AUM 34.31% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return

Superstring Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Superstring Capital Management held 43 positions worth $158M, up 13% from $140M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Superstring Capital Management withdrew a net $14.8M in Q2 2026, closing 11 positions and reducing 9 holdings. Its most notable exit was Summit Therapeutics, an estimated $16.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Revolution Medicines worth $9.56M.

  • Superstring Capital Management's largest Q2 2026 buy was Revolution Medicines: 51,053 shares worth $9.56M.
  • Superstring Capital Management added most to Axsome Therapeutics in Q2 2026, an estimated $9.26M increase.
  • Superstring Capital Management's biggest Q2 2026 reduction was UroGen Pharma, cutting an estimated $5.31M.
  • Superstring Capital Management fully exited Summit Therapeutics in Q2 2026, selling an estimated $16.9M.
  • Superstring Capital Management's ten largest holdings make up 64% of its $158M portfolio in Q2 2026.
  • Superstring Capital Management opened 8 new positions and closed 11 in Q2 2026.
  • Superstring Capital Management's portfolio value rose 13% quarter-over-quarter to $158M.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.